approval of ipilimumab, this observational cohort study (CA184-332) was
initiated to describe patient and disease characteristics, patterns of care,
survival, and adverse events (AEs) in advanced melanoma (AM) patients treated
with first-line ipilimumab in realworld US community practice. Methods: Adult
patients with treatment-naive AM who received ≥1 dose of ipilimumab 3 mg/kg between
April 2011 and September 2012 were retrospectively identified at US Oncology
sites. Clinical data were abstracted from patient medical records. Results:
Median age of the 157 patient cohorts was 66 years (range 21 - 91). 68.2% were
male, and 90.5% had a cutaneous primary site. At ipilimumab initiation, 80.9%
of patients had an ECOG performance status of 0 or 1; 54.1% were stage M1c;
34.4% had brain metastases; 24.8% had elevated lactate dehydrogenase, and 13.4%
were positive for BRAF mutation. All 4 cycles of ipilimumab were completed by
55.8% of patients. At a median follow-up of 8.5 months (range 2.9 - 15.0),
median overall survival was 11.5 months (95% CI: 8.9 - 16.6) and 1-year
survival was 46.7% (95% CI: 38.1 - 54.9). During ipilimumab treatment, AEs were
experienced by 63.7% of patients. The most frequent AEs were gastrointestinal
(41.4%; diarrhea in 19.1%) and skin-related (28.0%; rash in 17.8%); 17.8% of
patients had an AE that led to ipilimumab discontinuation. Conclusions: These
real-world results are consistent with those from clinical trials and provide
evidence supporting the effectiveness and safety of first-line ipilimumab 3
mg/kg monotherapy in patients with AM treated in a community practice setting.
Korn, E.L., Liu, P.Y., Lee, S.J., Chapman, J.A., Niedzwiecki, D., Suman, V.J., et al. (2008) Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials. Journal of Clinical Oncology, 26, 527-534.
Garbe, C., Eigentler, T.K., Keilholz, U., Hauschild, A. and Kirkwood, J.M. (2011) Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects. The Oncologist, 16, 5-24.
Hodi, F.S., O’Day, S.J., McDermott, D.F., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. (2010) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 363, 711-723. http://dx.doi.org/10.1056/NEJMoa1003466
Robert, C., Thomas, L., Bondarenko, I., O’Day, S., Weber, J., Garbe, C., et al. (2011) Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. New England Journal of Medicine, 364, 2517-2526.
Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., et al. (2011) Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine, 364, 2507-2516.
Weber, J.S., Kahler, K.C. and Hauschild, A. (2012) Management of Immune-Related Adverse Events and Kinetics of Response with Ipilimumab. Journal of Clinical Oncology, 30, 2691-2697.
Hersh, E.M., O’Day, S.J., Powderly, J., Khan, K.D., Pavlick, A.C., Cranmer, L.D., et al. (2011) A Phase II Multicenter Study of Ipilimumab with or without Dacarbazine in Chemotherapy-Na?ve Patients with Advanced Melanoma. Investigational New Drugs, 29, 489-498. http://dx.doi.org/10.1007/s10637-009-9376-8
Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., et al. (2011) A Prospective Phase II Trial Exploring the Association between Tumor Microenvironment Biomarkers and Clinical Activity of Ipilimumab in Advanced Melanoma. Journal of Translational Medicine, 9, 204. http://dx.doi.org/10.1186/1479-5876-9-204
Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., et al. (2013) Pooled Analysis of Long-Term Survival Data from Phase II and Phase III Trials of Ipilimumab in Metastatic or Locally Advanced, Unresectable Melanoma. European Cancer Congress 2013 (ECCO-ESMO-ESTRO), Amsterdam, 27 September-1 October 2013, Abstract LBA 24.
Margolin, K., Ernstoff, M.S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., et al. (2012) Ipilimumab in Patients with Melanoma and Brain Metastases: An Open-Label, Phase 2 Trial. The Lancet Oncology, 13, 459-465.
Di Giacomo, A.M., Ascierto, P.A., Pilla, L., Santinami, M., Ferrucci, P.F., Giannarelli, D., et al. (2012) Ipilimumab and Fotemustine in Patients with Advanced Melanoma (NIBIT M1): An Open-Label, Single-Arm Phase 2 Trial. The Lancet Oncology, 13, 879-886. http://dx.doi.org/10.1016/S1470-2045(12)70324-8
Ackerman, A., Klein, O., McDermott, D.F., Wang, W., Ibrahim, N., Lawrence, D.P., et al. (2014) Outcomes of Patients with Metastatic Melanoma Treated with Immunotherapy Prior to or after BRAF Inhibitors. Cancer, 120, 1695-1701. http://dx.doi.org/10.1002/cncr.28620
Ascierto, P.A. and Margolin, K. (2014) Ipilimumab before BRAF Inhibitor Treatment May Be More Beneficial than Vice Versa for the Majority of Patients with Advanced Melanoma. Cancer, 120, 1617-1619.
Margolin, K.A., Wong, S.L., Penrod, J.R., Song, J., Chang, I.F., Johnson, D.B., et al. (2013) Effectiveness and Safety of First-Line Ipilimumab 3 mg/kg Therapy for Advanced Melanoma: Evidence from a US Multisite Retrospective Chart Review. European Cancer Congress 2013 (ECCO-ESMO-ESTRO), Amsterdam, 27 September-1 October 2013, Abstract 3742.